BioSpace News Archive

RedHill Biopharma Ltd. announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes’ U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment.

Alkermes plc announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1.

REGENXBIO Inc. announced it will participate in Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.

United Therapeutics Corporation, announced that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024.

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a Non-Brokered Private Placement offering of units.

Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., announced that positive results from the Phase 3 oral zoliflodacin trial will be highlighted in an oral presentation given by the Global Antibiotic Research & Development Partnership at the European Society of Clinical Microbiology and Infectious Disease Global Congress taking place April 27-30, 2024, in Barcelona, Spain.

Nutriband Inc. announced that it has closed the $8.4 million private placement to fund the commercial development program for its lead product, AVERSA™ Fentanyl.

Senzime AB announces that the company’s annual and sustainability report for 2023 is published and available at the website.

CureVac N.V. today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024.

BioArctic AB’s partner Eisai published the preliminary global revenue for Leqembi during the first quarter 2024, in conjunction with their partner Biogen’s first quarter report.